

Gibson Dunn Advises BVF Partners L.P. on up to \$400 Million Financing for Immunic, Inc.

Firm News | February 25, 2026

Gibson Dunn represented BVF Partners L.P. as lead investor in the up to \$400 million private placement financing for Immunic, Inc., a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases.

Gibson Dunn regularly advises life sciences investors on large-scale private placement financings for biotechnology companies.

The Gibson Dunn team included Ryan Murr, Branden Berns, Karen Spindler, Nick Linke, and Lauren Romagnoli.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Karen A. Spindler](#)

[Nicholas G. Linke](#)

[Lauren Romagnoli](#)

Related Capabilities

[Life Sciences](#)

[Finance](#)

[Private Equity](#)

[Emerging Companies / Venture Capital](#)